Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OOP
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency reorganizes cancer drug reviews by disease type, while keeping leadership, as expected. After scheduled actions, applications will be migrating to their designated areas within the renamed Office of Hematology and Oncology Products.
You may also be interested in...
FDA Talent Hunt: Better To Recruit From Academia Than Industry?
CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention. In addition to fewer staff than needed to complete its work, FDA’s hiring problem makes it more difficult for the agency to stay abreast of new scientific discoveries and technology.
FDA Talent Hunt: Better To Recruit From Academia Than Industry?
CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention. In addition to fewer staff than needed to complete its work, FDA’s hiring problem makes it more difficult for the agency to stay abreast of new scientific discoveries and technology.
The Next Step In FDA Reform? Consolidated Drug/Device Groups Proposed By FOCR
A Friends of Cancer Research proposal to create FDA drug-device review teams in oncology, cardiology and neurodegenerative disease could find a home in the next round of FDA reform legislation. PDUFA VI. Current and former agency officials are cautiously optimistic about the idea, but combining review operations with different statutory underpinnings will be challenging.